Recent Advancements in the Treatment of Rectal Gastrointestinal Stromal Tumor: In Era of Imatinib.
Recent Advancements in the Treatment of Rectal Gastrointestinal Stromal Tumor: In Era of Imatinib.
复制标题
DOI：
10.2147/cmar.s352860
复制
发表时间：
2022
影响因子：
3.3
通讯作者：
Chen X
中科院分区：
文献类型：
--
作者：
Qu H;Xu Z;Ren Y;Gong Z;Ju RH;Zhang F;Kang H;Xu Y;Chen X
胃肠道间质瘤（GIST）是胃肠道最常见的间叶性肿瘤，年发病率为10-15例/百万。然而，直肠GIST的发病率较低，约占所有直肠肿瘤的0.1%。直肠GISTs的治疗仍存在争议，缺乏相对统一的指南和共识。治疗主要基于医生的临床经验。新辅助伊马替尼治疗的广泛应用使得治疗多样化，特别是在手术方式的选择上。本文就近年来直肠肿瘤治疗的最新进展进行综述，旨在为患者提供更系统、更个体化的治疗策略。
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumor of the gastrointestinal tract, with an annual incidence of 10–15 cases per million. However, rectal GIST has a low incidence, accounting for approximately 0.1% of all rectal tumors. The treatment of rectal GISTs is still controversial and the relative unified guidelines and consensus opinions are inadequate. Treatment is based primarily on the clinical experience of the physician. The widespread application of neoadjuvant imatinib therapy allows diversification of treatment, especially in the choice of surgical methods. Herein, we reviewed the most recent literature and summarized the new progress in rectal tumor treatment, with the aim of providing patients with more systematic and individualized therapeutic strategies.